Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Syphilis | 1 | 2025 | 6 | 0.930 |
Why?
|
| Anti-HIV Agents | 3 | 2014 | 20 | 0.480 |
Why?
|
| HIV Infections | 5 | 2023 | 165 | 0.440 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2009 | 2 | 0.310 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2009 | 10 | 0.310 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2009 | 22 | 0.310 |
Why?
|
| Anti-Bacterial Agents | 3 | 2025 | 540 | 0.250 |
Why?
|
| Syphilis, Congenital | 1 | 2025 | 3 | 0.230 |
Why?
|
| Penicillins | 1 | 2025 | 12 | 0.230 |
Why?
|
| Marburg Virus Disease | 1 | 2004 | 1 | 0.210 |
Why?
|
| Biological Warfare | 1 | 2004 | 6 | 0.210 |
Why?
|
| Ebolavirus | 1 | 2004 | 8 | 0.210 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2004 | 8 | 0.210 |
Why?
|
| RNA Viruses | 1 | 2004 | 6 | 0.210 |
Why?
|
| Pandemics | 1 | 2025 | 211 | 0.200 |
Why?
|
| HIV-1 | 3 | 2014 | 59 | 0.200 |
Why?
|
| Sexual and Gender Minorities | 1 | 2023 | 58 | 0.180 |
Why?
|
| Papillomavirus Vaccines | 1 | 2023 | 74 | 0.180 |
Why?
|
| Papillomavirus Infections | 1 | 2023 | 159 | 0.170 |
Why?
|
| Self-Directed Learning as Topic | 1 | 2020 | 3 | 0.170 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2020 | 65 | 0.150 |
Why?
|
| Humans | 14 | 2025 | 29202 | 0.150 |
Why?
|
| Students, Medical | 1 | 2020 | 102 | 0.150 |
Why?
|
| Myelin Proteolipid Protein | 1 | 1997 | 4 | 0.130 |
Why?
|
| Myelin Sheath | 1 | 1997 | 28 | 0.130 |
Why?
|
| Transgenes | 1 | 1997 | 63 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 1 | 1997 | 154 | 0.120 |
Why?
|
| Opportunistic Infections | 1 | 2015 | 17 | 0.110 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 28 | 0.110 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2015 | 44 | 0.110 |
Why?
|
| Immunization | 1 | 2015 | 133 | 0.110 |
Why?
|
| Drug Resistance, Viral | 1 | 2014 | 5 | 0.100 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 151 | 0.100 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2014 | 8 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 12 | 0.080 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 29 | 0.080 |
Why?
|
| Antigen Presentation | 1 | 2010 | 82 | 0.080 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2009 | 3 | 0.080 |
Why?
|
| Pyrimidinones | 1 | 2009 | 17 | 0.080 |
Why?
|
| Ritonavir | 1 | 2009 | 11 | 0.080 |
Why?
|
| Cytomegalovirus Infections | 1 | 2009 | 36 | 0.070 |
Why?
|
| Cryptococcosis | 1 | 2009 | 32 | 0.070 |
Why?
|
| Oligopeptides | 1 | 2009 | 97 | 0.070 |
Why?
|
| Pyridines | 1 | 2009 | 108 | 0.070 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2009 | 168 | 0.070 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2007 | 4 | 0.070 |
Why?
|
| Electrocardiography | 1 | 2009 | 398 | 0.070 |
Why?
|
| Anti-Retroviral Agents | 1 | 2007 | 16 | 0.070 |
Why?
|
| Herpesviridae Infections | 1 | 2007 | 17 | 0.070 |
Why?
|
| Rifamycins | 1 | 2007 | 2 | 0.070 |
Why?
|
| Nitrofurantoin | 1 | 2007 | 3 | 0.070 |
Why?
|
| Chloramphenicol | 1 | 2007 | 6 | 0.070 |
Why?
|
| Tinidazole | 1 | 2007 | 3 | 0.070 |
Why?
|
| Organophosphonates | 1 | 2007 | 7 | 0.070 |
Why?
|
| Adenine | 1 | 2007 | 17 | 0.070 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2007 | 10 | 0.070 |
Why?
|
| Drug Eruptions | 1 | 2007 | 7 | 0.070 |
Why?
|
| Metronidazole | 1 | 2007 | 16 | 0.060 |
Why?
|
| Male | 6 | 2023 | 14120 | 0.060 |
Why?
|
| Thiazoles | 1 | 2007 | 50 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2007 | 114 | 0.060 |
Why?
|
| Influenza, Human | 1 | 2007 | 101 | 0.060 |
Why?
|
| Skin | 1 | 2007 | 157 | 0.060 |
Why?
|
| Bioterrorism | 1 | 2004 | 28 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2023 | 17 | 0.050 |
Why?
|
| Survival Rate | 1 | 2004 | 433 | 0.050 |
Why?
|
| Sexual Partners | 1 | 2023 | 25 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2023 | 73 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 105 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2004 | 632 | 0.040 |
Why?
|
| Prognosis | 1 | 2004 | 817 | 0.040 |
Why?
|
| Female | 5 | 2015 | 15819 | 0.040 |
Why?
|
| HIV Protease Inhibitors | 2 | 2014 | 14 | 0.040 |
Why?
|
| Vaccination | 1 | 2023 | 222 | 0.040 |
Why?
|
| Program Development | 1 | 2020 | 88 | 0.040 |
Why?
|
| Middle Aged | 4 | 2015 | 7493 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2023 | 316 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 176 | 0.040 |
Why?
|
| Health Personnel | 1 | 2020 | 99 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 233 | 0.040 |
Why?
|
| Adult | 4 | 2015 | 8125 | 0.040 |
Why?
|
| Curriculum | 1 | 2020 | 307 | 0.040 |
Why?
|
| United States | 1 | 2004 | 2269 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2009 | 210 | 0.030 |
Why?
|
| Mice, Jimpy | 1 | 1997 | 1 | 0.030 |
Why?
|
| Blastocyst | 1 | 1997 | 6 | 0.030 |
Why?
|
| Brain Chemistry | 1 | 1997 | 22 | 0.030 |
Why?
|
| Oklahoma | 2 | 2014 | 1063 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 1021 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1997 | 131 | 0.030 |
Why?
|
| Base Sequence | 1 | 1997 | 589 | 0.030 |
Why?
|
| Myocardium | 1 | 1997 | 197 | 0.030 |
Why?
|
| Heart | 1 | 1997 | 232 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 1997 | 514 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 1997 | 1057 | 0.030 |
Why?
|
| Travel | 1 | 2015 | 12 | 0.030 |
Why?
|
| Immunization Schedule | 1 | 2015 | 20 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2015 | 47 | 0.030 |
Why?
|
| Aged | 2 | 2015 | 5647 | 0.030 |
Why?
|
| Adolescent | 2 | 2014 | 3254 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 250 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 462 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 580 | 0.020 |
Why?
|
| Brain | 1 | 1997 | 774 | 0.020 |
Why?
|
| HIV Antigens | 1 | 2010 | 3 | 0.020 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 2 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 13 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 24 | 0.020 |
Why?
|
| Viral Load | 1 | 2010 | 32 | 0.020 |
Why?
|
| Pregnancy | 1 | 2015 | 1261 | 0.020 |
Why?
|
| Amino Acids | 1 | 2010 | 85 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 264 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 103 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 875 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 290 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 358 | 0.020 |
Why?
|
| Atazanavir Sulfate | 1 | 2009 | 1 | 0.020 |
Why?
|
| Lopinavir | 1 | 2009 | 2 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 415 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 2144 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 239 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 453 | 0.020 |
Why?
|
| Disease Progression | 1 | 2010 | 483 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2015 | 2442 | 0.020 |
Why?
|
| African Americans | 1 | 2010 | 353 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2010 | 234 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2010 | 903 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 557 | 0.020 |
Why?
|
| Tenofovir | 1 | 2007 | 7 | 0.020 |
Why?
|
| Nitro Compounds | 1 | 2007 | 10 | 0.020 |
Why?
|
| Mice | 1 | 1997 | 4867 | 0.020 |
Why?
|
| Drug Resistance, Microbial | 1 | 2007 | 36 | 0.020 |
Why?
|
| Exanthema | 1 | 2007 | 14 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2014 | 2659 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 2007 | 56 | 0.020 |
Why?
|
| Young Adult | 1 | 2014 | 2875 | 0.020 |
Why?
|
| Time Factors | 1 | 2009 | 1619 | 0.010 |
Why?
|
| Animals | 1 | 1997 | 10802 | 0.010 |
Why?
|